ImmunityBio, Inc. 已向美国食品药品监督管理局（FDA）重新提交了其补充生物制剂许可申请（sBLA），该申请涉及将Anktiva®（nogapendekin alfa inbakicept）与卡介苗（BCG）联合用于治疗BCG无应答、伴有乳头状病变的非肌层浸润性膀胱癌（NMIBC）患者。此次重新提交是基于监管机构对额外数据的审查后进行的。
ImmunityBio, Inc. 已向美国食品药品监督管理局（FDA）重新提交了其补充生物制剂许可申请（sBLA），该申请涉及将Anktiva®（nogapendekin alfa inbakicept）与卡介苗（BCG）联合用于治疗BCG无应答、伴有乳头状病变的非肌层浸润性膀胱癌（NMIBC）患者。此次重新提交是基于监管机构对额外数据的审查后进行的。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.